title: The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis.
abstract: BACKGROUND
  Zoledronic acid is a new member of the bisphosphonate (BP) class of compounds, a family of closely related synthetic molecules originally derived from the naturally occurring pyrophosphate. These compounds that are potent inhibitors of bone resorption, have been shown to reduce the growth of several cancer cell lines in vitro, and can act as inhibitors of angiogenesis. The angiogenesis inhibitor TNP-470, a synthetic analogue of the fungal antibiotic fumagillin, has been shown to inhibit the growth of multiple tumors in vivo, and is currently in Phase II clinical trials for cancer.
  
  
  METHODS
  The effects of daily subcutaneous (s.c.) administration of zoledronic acid (0.1 mg/kg) were compared with those of TNP-470 (15 mg/kg/day and 30 mg/kg every other day, s.c.) in a nude mouse xenograft model for the childhood cancer, neuroblastoma (NB).
  
  
  RESULTS
  Zoledronic acid reduced the tumor growth by 33% whereas TNP-470 was less effective and reduced the tumor growth by 26% and 11% for animals treated with 15 mg/kg/day and 30 mg/kg every other day, respectively. Analysis of angiogenesis showed a significant reduction of the number of vessels per grid and in vessel length in all the treatment groups.
  
  
  CONCLUSIONS
  Zoledronic acid shows tumoristatic and angiostatic properties that might be beneficial in the treatment of solid tumors such as neuroblastoma.
authors.affiliation: Department of Medical Cell Biology, Children's Hospital, Uppsala University, Sweden.
authors.forename: Ulrika
authors.initials: U
authors.lastname: Bäckman
authors.forename: Asa
authors.initials: A
authors.lastname: Svensson
authors.forename: Rolf H
authors.initials: RH
authors.lastname: Christofferson
authors.forename: Faranak
authors.initials: F
authors.lastname: Azarbayjani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D003510:Cyclohexanes / Q000494:pharmacology; D004164:Diphosphonates / Q000494:pharmacology*; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D009447:Neuroblastoma / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays; D000077211:Zoledronic Acid
chemical_list: D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D004164:Diphosphonates; D007093:Imidazoles; D012717:Sesquiterpenes; D000077211:Zoledronic Acid; D000077609:O-(Chloroacetylcarbamoyl)fumagillol